Skills this job asks for
TranslationBudgetingFinancial modellingHR
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Feb 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Lyell Immunopharma INC paid sponsored hires in similar roles1 certified filing for “Senior Director, Medical Affairs, Solid Tumors” (Natural Sciences Managers) in CA: $291k–$291k, median $291k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Feb 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Lyell Immunopharma INC paid sponsored hires in similar roles
- 1 certified filing for “Senior Director, Medical Affairs, Solid Tumors” (Natural Sciences Managers) in CA: $291k–$291k, median $291k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.
This role will need to have frequent travel to our South San Francisco, CA office for in person meetings.
The Associate Director, FP&A is responsible for leading the company’s core financial planning and analysis activities, including annual budgeting, quarterly forecasting, monthly financial reporting, variance analysis, financial modeling, and business performance management. The Associate Director will partner closely with functional leaders across the organization to develop and manage financial plans, understand key business drivers, monitor performance, and provide actionable financial insights to support effective resource allocation and decision-making.
The Associate Director will serve as a key financial partner to R&D, Clinical, G&A, Commercial and other functional leaders, with a focus on understanding operational activities and their financial implications. The role will also be responsible for continuously improving the company’s FP&A processes, reporting, systems, forecasting capabilities, and financial discipline.
KEY ROLE AND RESPONSIBILITIES:
• Lead the annual budgeting and quarterly forecasting processes, coordinating cross-functional inputs, establishing timelines and assumptions, and ensuring forecasts accurately reflect current business plans and operational activities.
• Own the monthly FP&A reporting and performance management process, including actual versus budget and forecast analysis, KPI reporting, identification of key drivers and trends, and communication of actionable insights to Finance and business leaders.
• Partner with R&D, Clinical, G&A, Commercial, and other functional leaders to track spend, monitor performance, identify key cost drivers, including CRO and vendor costs, and provide timely financial analysis to support informed decision-making.
• Develop and maintain driver-based financial models that link operational assumptions to financial performance, including headcount, departmental expenses, clinical programs, CRO and vendor costs, and other significant spending categories.
• Lead headcount and operating expense planning and forecasting, partnering with Human Resources and functional leaders to understand resource requirements and assess their financial impact.
• Support the long-range planning process by coordi
Apply on employer site ↗